Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial

Official title:

A Phase II Study Of Whole-Brain Radiation Therapy With Thalidomide And Temozolomide In Patients With Newly Diagnosed Brain Metastases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00049361
• Other study ID #: REBACDR0000258057
• Secondary ID: CCCWFU-91102NCI-
• Status: Completed
• Phase: Phase 2
• Start date: January 1, 2004
• Est. completion date: December 7, 2004

Study information

• Verified date: September 2021
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation therapy with thalidomide and temozolomide may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining whole-brain radiation therapy with thalidomide and temozolomide in treating patients who have newly diagnosed brain metastases.

Description:

OBJECTIVES:

• Determine the overall median survival time of patients with newly diagnosed brain metastases treated with whole-brain radiotherapy in combination with thalidomide and temozolomide.

• Determine the radiographic response rate, median time to tumor progression, and median time to neurologic response and progression in patients treated with this regimen.

• Determine the cause of death of patients treated with this regimen.

• Determine the toxicity of this regimen in these patients.

• Assess quality of life of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients undergo radiotherapy daily 5 days a week for 3 weeks. Beginning on the day before the first radiation treatment, patients receive oral thalidomide once daily and oral temozolomide once daily for 21 days. Patients continue to receive thalidomide daily for up to 2 years in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, 1 and 3 months after completing radiotherapy, and then every 3 months thereafter.

Patients are followed at 1 and 3 months and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 10 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: December 7, 2004
• Est. primary completion date: December 7, 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed extracranial primary malignancy or brain metastases

• At least 1 brain metastasis with at least 1 unresected lesion that is measurable by contrast-enhanced MRI

• No evidence of spinal drop metastases or spread to noncontiguous meninges

• No lymphoma, small cell lung cancer, or germ cell tumor

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Karnofsky 70-100%

Life expectancy

• At least 4 months

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 10 g/dL

Hepatic

• Bilirubin less than 1.5 mg/dL

• SGPT and/or SGOT no greater than 2 times upper limit of normal

Renal

• Creatinine no greater than 1.5 mg/dL

• BUN no greater than 25 mg/dL

Other

• Able to be regularly followed

• No sensory neuropathy greater than grade 2

• No other major medical illnesses that would preclude study

• No neurologic or psychiatric impairments that would preclude study

• No active infection

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use at least 1 highly effective and 1 additional effective method of contraception during and for 2 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

• No other concurrent chemotherapy during and for 4 weeks after study

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiotherapy to head or neck

• No prior stereotactic radiosurgery

• Concurrent radiotherapy to extracranial sites of underlying malignancy allowed

Surgery

• Prior craniotomy allowed if completed within the past 10-28 days

Related Conditions & MeSH terms

• Brain and Central Nervous System Tumors
• Central Nervous System Neoplasms
• Neoplasms
• Nervous System Neoplasms
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Drug:
• temozolomide

• thalidomide

Radiation:
• radiation therapy

Locations

Country	Name	City	State
United States	CCOP - Central Illinois	Decatur	Illinois
United States	CCOP - Southeast Cancer Control Consortium	Goldsboro	North Carolina
United States	CCOP - Greenville	Greenville	South Carolina
United States	CCOP - Upstate Carolina	Spartanburg	South Carolina
United States	Comprehensive Cancer Center at Wake Forest University	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall median survival
Secondary	Radiographic response rate as assessed by MRI and RECIST one-dimensional criterion at 1 month, 3 months, and every 3 months thereafter
Secondary	Median time to tumor progression
Secondary	Median time to neurologic response and progression
Secondary	Cause of death at median time
Secondary	Quality of life as assessed by FACT-BT, FACT-F, and Beck Depression Inventory at 1 month, 3 months, and every 3 months thereafter
Secondary	Toxicity as assessed by NCI Common Toxicity Criteria (CTC) version 2.0 for up to 90 days